Hemery P, Congard P, Galmiche J P, Bonfils S
Clinique des Maladies de l'Appareil Digestif, CHU Nord, Nantes.
Drugs. 1988;35 Suppl 3:76-81. doi: 10.2165/00003495-198800353-00014.
The gastric antisecretory activity of roxatidine acetate was studied on 24-hour intragastric pH in 12 healthy male volunteers. The study was randomised, double-blind and double-dummy where either roxatidine acetate 150 mg as a slow release granulated formulation or placebo were administered at 7.30 pm or 10 pm. Roxatidine acetate 150 mg produced a significant decrease in the number of hours during which gastric acidity ranged between pH 1.5 and 4.0 which was consistent with the pharmacokinetic profile of the drug. There was no significant difference between the median intragastric pH values for early evening and bedtime administration of roxatidine acetate. The present data confirm that roxatidine acetate 150 mg inhibits gastric acid secretion but while a single evening dose is effective in controlling intragastric pH the results suggest there is no clear advantage in an early evening dose compared with a bedtime dose.
在12名健康男性志愿者中,研究了醋酸罗沙替丁对24小时胃内pH值的抗分泌活性。该研究采用随机、双盲和双模拟设计,于晚上7:30或10点给予150mg缓释颗粒制剂的醋酸罗沙替丁或安慰剂。150mg醋酸罗沙替丁使胃酸度在pH 1.5至4.0之间的小时数显著减少,这与该药物的药代动力学特征一致。傍晚和睡前服用醋酸罗沙替丁的胃内pH值中位数之间无显著差异。目前的数据证实,150mg醋酸罗沙替丁可抑制胃酸分泌,但虽然单次傍晚剂量可有效控制胃内pH值,但结果表明,与睡前剂量相比,傍晚剂量并无明显优势。